Cheyenne Regional Medical Center

Cheyenne, Wyoming 82001

0 studies enrolling now · 4 studies all time

What they study most

Acute Myeloid Leukemia (AML) With, Chemotherapy-induced Nausea and Vomiting, FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD), First Line Non-Small Cell Lung Cancer, Primary Prevention of Sudden Cardiac Arrest, Secondary Prevention of Sudden Cardiac Arrest

Studies at this site

• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• Longitudinal Surveillance Study of the 4-SITE Lead/Header System — Completed
• Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy — NO_LONGER_AVAILABLE
• A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer — Completed